Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 13
2003 13
2004 16
2005 12
2006 16
2007 20
2008 12
2009 6
2010 12
2011 12
2012 7
2013 3
2014 11
2015 9
2016 14
2017 11
2018 14
2019 12
2020 12
2021 21
2022 20
2023 25
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
Leonard S, Jones AN, Newman L, Chavez-MacGregor M, Freedman RA, Mayer EL, Mittendorf EA, King TA, Kantor O. Leonard S, et al. Among authors: newman l. Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308-8. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38649618
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: newman l. Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9. Cancer Lett. 2024. PMID: 38199587 Free article.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: newman l. bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406. bioRxiv. 2023. PMID: 38076873 Free PMC article. Updated. Preprint.
277 results